NEW: FDA's Julie Tierney and Dr. Nicole Verdun to Speak at ASGCT's Policy Summit (Sept. 23-24). Register Now!
Membership Council Chair (2022-2025)
Ms. Wellman is chief operating officer at Akouos and has 20 years of experience in AAV vector gene therapy research and development. In her previous role at Spark Therapeutics, of which she is a co-founder, Ms. Wellman led the regulatory and clinical development for several AAV gene therapies, including Luxturna, the first FDA-approved gene therapy for a genetic disease.
September 23-24, 2024 | Washington, D.C.
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico